Assertio stock surges after raising Garda merger price By Investing.com

Assertio agreed to an amended all-cash merger with Garda Therapeutics at $21.80 per share, valuing the company at $153.2 million and lifting the offer 21.1% from Garda’s April 8 proposal. The revised deal follows a window-shop process and includes fully committed equity and debt financing; Assertio’s board says it is the most favorable outcome for stockholders. Assertio shares rose 16% on the news, and the transaction is expected to close in Q2 2026 subject to tender and other customary conditions.

Analysis

ASRT’s move is less about deal math than about signaling value leakage being capped. Once a sponsor or strategic buyer has to lift price after a window-shop process, the market typically re-rates the target toward deal-certainty rather than standalone fundamentals, which compresses downside unless financing or shareholder acceptance becomes an issue. The main second-order winner is any holder of small-cap special situations that can now underwrite a higher floor for busted-merger optionality.

The real risk is not price, but time: deal spread can still widen if tender conditions get sticky, especially when a majority-of-shares condition remains outstanding. In the near term, the stock will trade like a financing/tender-balance sheet event rather than an operating business, so any delay pushes annualized return sharply lower even if headline price stays intact. That makes the opportunity most attractive to capital willing to sit through 1-2 quarters of event risk rather than momentum traders.

The contrarian angle is that the improved offer may be enough to flush out residual arbitrage demand, leaving little incremental upside from here. If the market had already priced in a competing bid, the latest increase mostly validates the floor rather than creating a fresh rerate. The higher-probability mistake is chasing the last dollar of spread while ignoring break-risk on financing, tender logistics, or a deteriorating bid environment.

From a competitive-dynamics lens, Garda is likely paying up to avoid being outbid or appearing structurally weak, which can matter in future tuck-in M&A: once a bidder shows willingness to stretch, subsequent targets may anchor higher. That is mildly negative for other small-cap healthcare acquirers seeking takeouts, because it raises the bar for acceptable premiums and reduces optionality for buyers with limited balance-sheet flexibility.

Key Decisions for Investors

• Long ASRT only as an event-driven stub, not a directional equity: initiate near/under the revised offer price and hold through tender completion over 1-2 quarters; expected upside is limited but downside should be capped unless deal friction emerges.
• Sell call spreads on ASRT against existing long shares if liquidity allows: monetize the reduced upside after the increased offer while keeping exposure to a higher-probability close; best suited for the next 30-60 days.
• For merger-arb desks, compare ASRT’s annualized spread to other healthcare takeout names with cleaner financing; rotate capital out of ASRT if the implied annualized return drops below peers by ~300-500 bps.
• Avoid chasing long ASRT after the reprice unless a new topping bid is credible; risk/reward deteriorates materially once the market has digested most of the revised premium.
• Monitor for spread tightening versus closing odds: if tender acceptance remains soft or financing terms reprice, expect 1-2 week volatility spikes that can create better entry points rather than immediate upside continuation.